APA (7th ed.) Citation

AGM, S., S, W., S, S., LM, M., ASB, E., H, B., . . . AG, B. (2024). A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss. Nature communications, 15(1), 1896. https://doi.org/10.1038/s41467-024-45784-0

Chicago Style (17th ed.) Citation

AGM, Schilder, Wolpert S, Saeed S, Middelink LM, Edge ASB, Blackshaw H, Pastiadis K, and Bibas AG. "A Phase I/IIa Safety and Efficacy Trial of Intratympanic Gamma-secretase Inhibitor as a Regenerative Drug Treatment for Sensorineural Hearing Loss." Nature Communications 15, no. 1 (2024): 1896. https://doi.org/10.1038/s41467-024-45784-0.

MLA (9th ed.) Citation

AGM, Schilder, et al. "A Phase I/IIa Safety and Efficacy Trial of Intratympanic Gamma-secretase Inhibitor as a Regenerative Drug Treatment for Sensorineural Hearing Loss." Nature Communications, vol. 15, no. 1, 2024, p. 1896, https://doi.org/10.1038/s41467-024-45784-0.